<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xsi:schemaLocation="http://www.sec.gov/edgar/thirteenffiler eis_13F_Filer.xsd" xmlns="http://www.sec.gov/edgar/thirteenffiler" xmlns:ns1="http://www.sec.gov/edgar/common" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>13F-NT</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <flags>
        <confirmingCopyFlag>false</confirmingCopyFlag>
        <returnCopyFlag>true</returnCopyFlag>
        <overrideInternetFlag>false</overrideInternetFlag>
      </flags>
      <filer>
        <credentials>
          <cik>0001687968</cik>
          <ccc>XXXXXXXX</ccc>
        </credentials>
      </filer>
      <periodOfReport>12-31-2019</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <reportCalendarOrQuarter>12-31-2019</reportCalendarOrQuarter>
      <filingManager>
        <name>Bain Capital Life Sciences Fund, L.P.</name>
        <address>
          <ns1:street1>200 Clarendon Street</ns1:street1>
          <ns1:city>Boston</ns1:city>
          <ns1:stateOrCountry>MA</ns1:stateOrCountry>
          <ns1:zipCode>02116</ns1:zipCode>
        </address>
      </filingManager>
      <reportType>13F NOTICE</reportType>
      <form13FFileNumber>028-18478</form13FFileNumber>
      <otherManagersInfo>
        <otherManager>
          <form13FFileNumber>28-18477</form13FFileNumber>
          <name>Bain Capital Life Sciences Investors, LLC</name>
        </otherManager>
        <otherManager>
          <form13FFileNumber>28-18476</form13FFileNumber>
          <name>Bain Capital Life Sciences Partners, LP</name>
        </otherManager>
      </otherManagersInfo>
      <provideInfoForInstruction5>Y</provideInfoForInstruction5>
      <additionalInformation>The report on Form 13F for the period ended December 31, 2019 for Bain Capital Life Sciences Fund, L.P. (the "Fund") is being filed by Bain Capital Life Sciences Investors, LLC, which is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of the Fund.</additionalInformation>
    </coverPage>
    <signatureBlock>
      <name>Adam Koppel</name>
      <title>Managing Dir. of Bain Capital Life Sciences Investors, LLC</title>
      <phone>617-516-2000</phone>
      <signature>/s/: Adam Koppel</signature>
      <city>Boston</city>
      <stateOrCountry>MA</stateOrCountry>
      <signatureDate>02-14-2020</signatureDate>
    </signatureBlock>
  </formData>
</edgarSubmission>
